{ "as_of": "2026-11-06", "cmr": "ca-cm-kg/TSXV/MRVL", "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.", "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Marvel Biosciences Corp. (TSXV: MRVL) — research page\n\nAs of 2026-11-06 · ca-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Marvel Biosciences Corp., listed on the TSXV under ticker MRVL, with ISIN CA57384M1077. The LEI is not on the record, as the ISIN is not in the GLEIF ISIN-to-LEI mapping file. Its security type is Corporate, its sector is Life Sciences, and its segment and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 15 filings in the twelve months to 2026-11-06, across 14 filing days. Of these, 2 are exchange bulletins and 13 are newswire releases. The median gap between filing days is 8 days. The latest filing is dated 2026-10-19, is a newswire release, and is 18 days before the record date. The exchange median is 9 filings, a cadence gap of 19 days, and a latency of 17.0 days across 1427 issuers. The sector median is 7.0 filings, a cadence gap of 17.5 days, and a latency of 14 days across 200 issuers. The issuer's filing count is above the exchange median and below the sector median, and its cadence gap is below the exchange median and below the sector median.\n\n## Auditor\n\nThe auditor of record is not on the record, and no auditor location is on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change, domicile change or segment move events. The halt flag is listed, not halted.\n\n## Orderability\n\nUnder rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, with the chapter as of 2026-11-04, the outcome is determinable for both client categories: paragraph (o) of the definition and paragraph (q) of the definition. Both carry signal ACM-200.\n\n## Coverage\n\nNo research houses are named on the issuer's investor-relations page, and none was found on the pages read. The count is 0.\n\n## Open research\n\nNo openly published research notes are on the record. The count is 0.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe vintage is not sealed for this market, and no issuer years are sealed. The live record began on 2026-09-10. Years 2021 through 2026 are sealed in the store but not served as of a date, and the as-of door answers not_sealed.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.tsx.com/json/company-directory/search/tsxv/^* (identity.exchange)\n- https://www.marketscreener.com/quote/stock/MARVEL-BIOSCIENCES-CORP-124599011 (identity.isin)\n- https://www.tsx.com/en/resource/571 (identity.sector)\n- https://mcp.ca-cm-kg.ai/events/TSXV/MRVL (the disclosure lines)\n- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)\n- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.ca-cm-kg.ai/record/TSXV/MRVL (the record)\n", "market": "CA", "node": "ca-cm-kg", "numbers": { "as_of_depth": { "issuer_years_sealed": [], "live_record_began": "2026-09-10", "node_history_from": null, "node_years_sealed": [], "note": "6 years are sealed in the CA store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06", "record_version": 1, "sealed": false, "store_years_sealed_not_served": [ "2021", "2022", "2023", "2024", "2025", "2026" ] }, "auditor": { "auditor": { "market": "CA", "reason": "none found", "state": "not_on_record" }, "auditor_firm_id": { "market": "CA", "state": "not_on_record" }, "auditor_location": { "market": "CA", "state": "not_on_record" }, "changes": [] }, "cmr": "ca-cm-kg/TSXV/MRVL", "coverage": { "count": 0, "houses": [], "pages_checked": [], "read_by": "Perplexity sonar (search) · page read by this rail", "read_date": "2026-11-12", "since": null, "state": "none_found" }, "disclosure": { "against": { "exchange": { "issuers": 1427, "median_cadence_gap_days": 19, "median_filings": 9, "median_latency_days": 17, "name": "TSXV" }, "sector": { "issuers": 200, "median_cadence_gap_days": 17.5, "median_filings": 7, "median_latency_days": 14, "name": "Life Sciences" } }, "by_type": { "exchange_bulletin": 2, "newswire_release": 13 }, "cadence_median_gap_days": 8, "filing_days": 14, "filings": 15, "latency_days": 18, "latest": [ { "category": null, "date": "2026-10-19", "source": "https://www.globenewswire.com/news-release/2026/10/19/3383228/0/en/marvel-biosciences-advances-mb-204-toward-first-in-human-testing-selects-cmax-as-phase-i-clinical-trial-site.html", "title": "Marvel Biosciences Advances MB-204 Toward First-in", "type": "newswire_release" }, { "category": null, "date": "2026-10-08", "source": "https://www.globenewswire.com/news-release/2026/10/08/3377091/0/en/marvel-biosciences-reports-mb-204-as-highly-effective-at-treating-autism-behaviours-in-shank3-mouse-model.html", "title": "Marvel Biosciences Reports MB-204 as Highly Effective at", "type": "newswire_release" }, { "category": null, "date": "2026-10-08", "source": "http://apps.tmx.com/TSXVenture/TSXVentureHttpController?GetPage=NoticesContents&PO_ID=&NOTICE_ID=321950&CORRECTION_FLG=N&HC_FLAG1=checked", "title": "TSXV bulletin: PP-N-B (Financings that are not done thru an Exchange Offering Prospectus)", "type": "exchange_bulletin" }, { "category": null, "date": "2026-10-06", "source": "https://www.globenewswire.com/news-release/2026/10/06/3375295/0/en/marvel-biosciences-signs-letter-of-intent-with-novatech-for-phase-1-trial-of-mb-204-and-provides-corporate-update.html", "title": "Marvel Biosciences Signs Letter of Intent with Novatech for", "type": "newswire_release" }, { "category": null, "date": "2026-09-17", "source": "https://www.newsfilecorp.com/release/314827/Marvel-Biosciences-fait-le-point-sur-un-placement-priv-pouvant-atteindre-3-millions-de-dollars", "title": "Marvel Biosciences fait le point sur un placement privé ...", "type": "newswire_release" } ], "latest_filing_date": "2026-10-19", "read": "the node's event lines (list_events_since), as get_filings serves them", "source": "https://mcp.ca-cm-kg.ai/events/TSXV/MRVL", "window": { "from": "2025-11-06", "to": "2026-11-06" } }, "identity": { "exchange": { "read_by": "tsx.com company directory (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*", "state": "sourced", "value": "TSXV" }, "isin": { "read_by": "Tavily search + regex extraction from page text", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.marketscreener.com/quote/stock/MARVEL-BIOSCIENCES-CORP-124599011", "state": "sourced", "value": "CA57384M1077" }, "jurisdiction": { "market": "CA", "reason": "none found", "state": "not_on_record" }, "lei": { "market": "CA", "reason": "ISIN not in the GLEIF ISIN-to-LEI mapping file", "state": "not_on_record" }, "name": { "read_by": "tsx.com company directory (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*", "state": "sourced", "value": "Marvel Biosciences Corp." }, "sector": { "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)", "state": "sourced", "value": "Life Sciences" }, "security_type": { "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)", "state": "sourced", "value": "Corporate" }, "segment": { "market": "CA", "state": "not_on_record" }, "ticker": { "read_by": "tsx.com company directory (exchange list)", "read_date": "2026-11-06", "read_date_basis": "the record version as_of", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*", "state": "sourced", "value": "MRVL" }, "website": { "market": "CA", "state": "not_on_record" } }, "licensed": { "columns": [ "licensor", "entitlement", "title", "date", "source" ], "rows": [], "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded." }, "lifecycle": { "delisting": [], "domicile_change": [], "listing": [], "name_change": [], "segment_move": [] }, "market": "CA", "node": "ca-cm-kg", "numbers_hash": "sha256:e8cc4136bd6ebb20fe1f243f4e86311431b2b1bc10e0756dc4346b36da064c32", "open_research": { "read_date": "2026-11-12", "rows": [], "state": "none_found" }, "orderability": { "chapter_as_of": "2026-11-04", "client_categories": [ "Paragraph (o) of the definition", "Paragraph (q) of the definition" ], "outcomes": { "Paragraph (o) of the definition": { "determinable": true, "signal": "ACM-200" }, "Paragraph (q) of the definition": { "determinable": true, "signal": "ACM-200" } }, "read": { "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group", "chapter": "https://mcp.ca-cm-kg.ai/book/aio.json", "door": "https://mcp.ca-cm-kg.ai/mcp", "tool": "get_orderability" }, "rule_version": "acm-68000/ca/kyp-know-your-product-ni-31-103/r1", "section": "ca.aio.v11" }, "record": { "as_of": "2026-11-06", "url": "https://mcp.ca-cm-kg.ai/record/TSXV/MRVL", "version": 1 }, "schema": "research-numbers v0.1 (USR-01, 2026-11-11)", "status": { "read_date": "2026-11-08", "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100", "value": "listed, not halted" } }, "numbers_hash": "sha256:e8cc4136bd6ebb20fe1f243f4e86311431b2b1bc10e0756dc4346b36da064c32", "path": "/ca/TSXV/MRVL", "schema": "research-page v0.1 (USR-02, 2026-11-11)", "sections": [ { "id": "identity", "text": "The issuer is Marvel Biosciences Corp., listed on the TSXV under ticker MRVL, with ISIN CA57384M1077. The LEI is not on the record, as the ISIN is not in the GLEIF ISIN-to-LEI mapping file. Its security type is Corporate, its sector is Life Sciences, and its segment and jurisdiction are not on the record. Its listing status is listed, not halted.", "title": "Identity and listing" }, { "id": "disclosure", "text": "The record holds 15 filings in the twelve months to 2026-11-06, across 14 filing days. Of these, 2 are exchange bulletins and 13 are newswire releases. The median gap between filing days is 8 days. The latest filing is dated 2026-10-19, is a newswire release, and is 18 days before the record date. The exchange median is 9 filings, a cadence gap of 19 days, and a latency of 17.0 days across 1427 issuers. The sector median is 7.0 filings, a cadence gap of 17.5 days, and a latency of 14 days across 200 issuers. The issuer's filing count is above the exchange median and below the sector median, and its cadence gap is below the exchange median and below the sector median.", "title": "The disclosure read" }, { "id": "auditor", "text": "The auditor of record is not on the record, and no auditor location is on the record. The record holds no auditor changes.", "title": "Auditor" }, { "id": "events", "text": "The record holds no listing, delisting, name change, domicile change or segment move events. The halt flag is listed, not halted.", "title": "Events and halts" }, { "id": "orderability", "text": "Under rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, with the chapter as of 2026-11-04, the outcome is determinable for both client categories: paragraph (o) of the definition and paragraph (q) of the definition. Both carry signal ACM-200.", "title": "Orderability" }, { "id": "coverage", "text": "No research houses are named on the issuer's investor-relations page, and none was found on the pages read. The count is 0.", "title": "Coverage" }, { "id": "open_research", "text": "No openly published research notes are on the record. The count is 0.", "title": "Open research" }, { "id": "licensed", "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.", "title": "Licensed" }, { "id": "depth", "text": "The vintage is not sealed for this market, and no issuer years are sealed. The live record began on 2026-09-10. Years 2021 through 2026 are sealed in the store but not served as of a date, and the as-of door answers not_sealed.", "title": "As-of depth" }, { "id": "sources", "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.", "title": "Sources" } ], "sources": [ { "for": "identity.exchange", "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*" }, { "for": "identity.isin", "source": "https://www.marketscreener.com/quote/stock/MARVEL-BIOSCIENCES-CORP-124599011" }, { "for": "identity.sector", "source": "https://www.tsx.com/en/resource/571" }, { "for": "the disclosure lines", "source": "https://mcp.ca-cm-kg.ai/events/TSXV/MRVL" }, { "for": "the halt flag", "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100" }, { "for": "the orderability chapter", "source": "https://mcp.ca-cm-kg.ai/book/aio.json" }, { "for": "the record", "source": "https://mcp.ca-cm-kg.ai/record/TSXV/MRVL" } ], "title": "Marvel Biosciences Corp. (MRVL) — research page", "writer": { "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers", "engine": "claude-haiku-5-5" } }